Malignant Soft-Tissue Sarcomas

Brownstein, Jeremy; DeLaney, Thomas F.

doi:10.1016/j.hoc.2019.08.022

Cited by 21 publications

(17 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Soft-tissue sarcomas (STSs) are a heterogeneous group of diseases of mesenchymal origin [1]. The prognosis of advanced STS is poor with a median survival of 17e24 months [2e5].…”

Section: Introductionmentioning

confidence: 99%

A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

Hirbe

Eulo

Moon

et al. 2020

European Journal of Cancer

View full text Add to dashboard Cite

Background: Cytotoxic chemotherapy remains the standard of care first-line treatment for advanced and metastatic soft-tissue sarcomas (STSs). Certain patients may not be chemotherapy candidates based upon age or co-morbidities, leaving limited treatment options. Pazopanib is a multi-targeted tyrosine kinase inhibitor that is FDA-approved for metastatic STS after the first line. We proposed a phase II study evaluating pazopanib as a first-line agent in patients with advanced disease who are deemed not to be candidates for chemotherapy. Methods: Eligible patients were at least 18 years old, not candidates for chemotherapyand were treatment naive. Pazopanib was titrated from 200 mg twice daily to a goal of 800 mg

show abstract

“…Soft-tissue sarcomas (STSs) are a heterogeneous group of diseases of mesenchymal origin [1]. The prognosis of advanced STS is poor with a median survival of 17e24 months [2e5].…”

Section: Introductionmentioning

confidence: 99%

A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

Hirbe

Eulo

Moon

et al. 2020

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Sarcomas are a subtle category of tumors that, depending on their location, may remain silent until reaching a significative volume. If diagnosed promptly, a safe margin resection may result in definitive treatment [8]. This, however, often implies a significative remaining defect.…”

Section: Discussionmentioning

confidence: 99%

Lymphatic Complications Prevention and Soft Tissue Reconstruction after Soft Tissue Sarcoma Resection in the Limbs

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: The definitive treatment of soft tissue sarcomas (STS) requires a radical surgical removal of the tumor, which often leads to large soft tissue defects. When they are located in the limbs, significant damage to the lymphatic pathways is not uncommon. In the present article, we present different techniques aimed at both reconstructing the defect and restoring sufficient lymph drainage, thus preventing short- and long-term lymphatic complications. Materials and Methods: Between 2018 and 2020, 10 patients presenting a soft tissue defect with lymphatic impairment received a locoregional reconstruction by means of either pedicled or free SCIP flap. Seven patients required a second flap to reach a good dead space obliteration. In six cases, we performed an interpositional flap, namely a soft tissue transfer with lymphatic tissue preservation, and in four cases a lymphatic flow-through flap. In all cases, the cause of the defect was STS surgical excision. The average age was 60.5 years old (ranging 39–84), seven patients were females and six were males. Results: All the patients were successfully treated. In two cases, minor post-operative complications were encountered (infected seroma), which were conservatively managed. No secondary procedures were required. The average follow-up was 8.9 months (ranging 7–12 months). No signs of lymphedema were reported during this time. In all cases, complete range of motion (ROM) and a good cosmetic result were achieved. Conclusions: A reconstructive procedure that aims not only to restore the missing volume, but also the lymphatic drainage might successfully reduce the rate of postoperative complications. Both lymphatic interpositional flaps and lymphatic flow-through flaps could be effective, and the right choice must be done according to each patient’s needs.

show abstract

“…Both gene copy number gain and loss are detected in different cancer types. For example, tumor suppressor genes such as TP53 and RB1 are found mutated while amplification of MDM2, CKD4 are detected in various sarcoma types (1).…”

Section: In Genomic Settingsmentioning

confidence: 99%

“…Soft tissue sarcomas are a collection of highly aggressive malignancies often present with slow growing lumps with or without pain (1). They can occur in all age groups and account for 1% of cancers in adults and 15% of cancers in children (2).…”

mentioning

confidence: 99%

“…The proper diagnosis largely depends on the features under microscope. Based on the immunohistochemistry markers and patterns of tumor cell arrangement, this group of rare diseases are divided into more than 50 different histological types (1). Due to the low incidence but complexity of this collection of diseases, the differential diagnosis can be very challenging.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy

Wei

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Soft tissue sarcomas are a set of malignancies of mesenchymal origin. Due to the rarity and similarity in clinical presentation, they are grouped together and treated similarly in clinic. The response rates for current chemotherapy are around 20% and the median overall survival for advanced soft tissue sarcoma are less than 2 years. Thus, the current strategy with identical treatment for all soft tissue sarcomas is far from satisfactory. In this study, we first reviewed the current clinical and genomic findings of soft tissue sarcoma, paying special attention to the heterogeneities among different tumors. Then we reviewed the state-of-art understanding of targeted therapy in soft tissue sarcoma. We observed tremendous heterogeneity both in clinical and genomic settings between different tumors. Individualized treatment plans demonstrated better response and disease control and should be advocated. In summary, heterogeneity of soft tissue sarcomas requires the development of individualized treatment plans such as targeted therapy.

show abstract

Malignant Soft-Tissue Sarcomas

Cited by 21 publications

References 70 publications

A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

Lymphatic Complications Prevention and Soft Tissue Reconstruction after Soft Tissue Sarcoma Resection in the Limbs

Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy

Contact Info

Product

Resources

About